Fampridine
Potassium Channel Blocker — NERVOUS SYSTEM
Also known as: 4-aminopyridine, ampyra, dalfampridine, fampyra, pyridin-4-amine
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Fampridine is a drug in the Potassium Channel Blocker class catalogued in DrugCentral. It was first approved by the FDA in 2010. Its mechanism of action is classified as Potassium Channel Antagonists. DrugCentral lists 3 molecular targets, including Kcnc2, Kcnc1 and KCNQ3|KCNQ2|KCNH1|KCNA2|KCNA6|KCNA3|KCNA4|KCNA5|KCNC1|KCNQ1|KCNQ4|KCNC4|KCNA1|KCNH2|KCNC3|KCNB1|KCNA10|KCNV1|KCNH5|KCNG3|KCNG4|KCNV2|KCNB2|KCNS1|KCNH8|KCNC2|KCNA7|KCNS3|KCNH6|KCNF1|KCNQ5|KCNH7|KCND1|KCND2|KCNG1|KCNG2|KCND3|KCNH3|KCNS2|KCNH4. Recorded indications include Multiple sclerosis.
- Drug class: Potassium Channel Blocker.
- Mechanism of action: Potassium Channel Antagonists.
- Molecular targets: Kcnc2, Kcnc1 and KCNQ3|KCNQ2|KCNH1|KCNA2|KCNA6|KCNA3|KCNA4|KCNA5|KCNC1|KCNQ1|KCNQ4|KCNC4|KCNA1|KCNH2|KCNC3|KCNB1|KCNA10|KCNV1|KCNH5|KCNG3|KCNG4|KCNV2|KCNB2|KCNS1|KCNH8|KCNC2|KCNA7|KCNS3|KCNH6|KCNF1|KCNQ5|KCNH7|KCND1|KCND2|KCNG1|KCNG2|KCND3|KCNH3|KCNS2|KCNH4 (3 listed in DrugCentral).
- Indications: Multiple sclerosis.
- ATC code: N07XX07 (Other nervous system drugs).
- Molecular formula: C5H6N2; molecular weight 94.12 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Multiple sclerosis
Contraindications (2)
- Impaired renal function disorder
- Seizure disorder
Mechanism & targets
| Mechanism of action (MoA) | Potassium Channel Antagonists |
|---|---|
| Established pharmacologic class | Potassium Channel Blocker |
Molecular targets (3)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Potassium voltage-gated channel subfamily C member 2 | Kcnc2 | blocker | IC50 4.60 |
| Potassium voltage-gated channel subfamily C member 1 | Kcnc1 | blocker | IC50 4.50 |
| Voltage-gated potassium channel | KCNQ3|KCNQ2|KCNH1|KCNA2|KCNA6|KCNA3|KCNA4|KCNA5|KCNC1|KCNQ1|KCNQ4|KCNC4|KCNA1|KCNH2|KCNC3|KCNB1|KCNA10|KCNV1|KCNH5|KCNG3|KCNG4|KCNV2|KCNB2|KCNS1|KCNH8|KCNC2|KCNA7|KCNS3|KCNH6|KCNF1|KCNQ5|KCNH7|KCND1|KCND2|KCNG1|KCNG2|KCND3|KCNH3|KCNS2|KCNH4 | blocker | IC50 4.05 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2010-01-22 | FDA | — | ACORDA | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
N07XX07 | NERVOUS SYSTEM › OTHER NERVOUS SYSTEM DRUGS › OTHER NERVOUS SYSTEM DRUGS › Other nervous system drugs |
Pharmacogenomics
Drug-label and guideline annotations from PharmGKB and CPIC.
- EMA label: SLC22A2
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Multiple sclerosis relapse | 3561.3 |
| Urinary tract infection | 2106.2 |
| Multiple sclerosis | 1480.5 |
| Balance disorder | 1338.9 |
| Laboratory test abnormal | 1240.1 |
| Fall | 1208.3 |
| Gait disturbance | 1053.2 |
| Therapy cessation | 725.7 |
| Urine analysis abnormal | 660.2 |
| Muscular weakness | 582.4 |
| Muscle spasticity | 577.6 |
| Seizure | 548.0 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Fampridine is on its molecule page.
| Molecular formula | C5H6N2 |
|---|---|
| Molecular weight | 94.12 g/mol |
| CAS number | — |
| InChIKey | NUKYPUAOHBNCPY-UHFFFAOYSA-N |
| PubChem CID | 1727 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Fampridine used for?
DrugCentral lists the following indications for Fampridine: Multiple sclerosis.
How does Fampridine work?
Fampridine is classified as Potassium Channel Antagonists; its molecular targets in DrugCentral include Kcnc2 (blocker), Kcnc1 (blocker) and KCNQ3|KCNQ2|KCNH1|KCNA2|KCNA6|KCNA3|KCNA4|KCNA5|KCNC1|KCNQ1|KCNQ4|KCNC4|KCNA1|KCNH2|KCNC3|KCNB1|KCNA10|KCNV1|KCNH5|KCNG3|KCNG4|KCNV2|KCNB2|KCNS1|KCNH8|KCNC2|KCNA7|KCNS3|KCNH6|KCNF1|KCNQ5|KCNH7|KCND1|KCND2|KCNG1|KCNG2|KCND3|KCNH3|KCNS2|KCNH4 (blocker).
When was Fampridine first approved?
Fampridine was first approved by the FDA in 2010.
What drug class does Fampridine belong to?
Fampridine is in the Potassium Channel Blocker class.
What is the chemical formula of Fampridine?
Fampridine has the molecular formula C5H6N2 and a molecular weight of 94.12 g/mol.
Browse: all drugs starting with F · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4163 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL284348 — compound record and bioactivity
- PubChem CID 1727 — chemical identifiers
- DrugBank DB06637 — drug record
- FDA UNII BH3B64OKL9 — substance identity
- DailyMed: FDA labels for Fampridine — current prescribing information (label search)
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
- PharmGKB / CPIC — pharmacogenomic label annotations
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.